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Abstract
Following transplantation, graft rejection continues to be a significant cause of
negative patient outcomes. Programmed cell death events are, in turn, significant contributors
to the delayed function and rejection of transplanted organs. We have previously
demonstrated that inhibition of necroptosis prevents murine microvascular endothelial cell
(MVEC) death and can attenuate murine graft rejection. In this study, we examined the
mitochondrial permeability transition pore (mPTP) and its regulator molecule, cyclophilin-D
(Cyp-D). Opening of the mPT pore triggers apoptotic molecules release and ultimately
results in cell death. However, the role of mPTP in the necroptotic pathway and in
transplantation rejection remains unclear. Here we found that TNFα triggered MVEC to
undergo receptor-interacting protein kinase family (RIPK1/3)-dependent necroptosis.
Interestingly, the inhibition of either mPTP opening or Cyp-D protected MVECs from
necroptosis; inhibition or deficiency of Cyp-D alone attenuated RIPK3-downstream mixed
lineage kinase domain like protein (MLKL) phosphorylation. Furthermore, Cyp-D-deficient
cardiac grafts showed prolonged survival in allogeneic BALB/c mice post transplantation in
comparison to wild- type grafts. Our study suggests that the mPTP may be an important
mechanistic mediator of necroptosis in cardiac grafts, and that targeting its opening via the
inhibition of Cyp-D presents therapeutic potential in the mitigation of cell death and cardiac
graft rejection.
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Chapter 1

1

Introduction

1.1 Current challenges in cardiac transplant rejection
For patients with chronic heart failure, heart transplantation is typically the
preferred therapy. However, despite an improvement in the one-year survival rate of heart
transplant recipients of up to 90% by 2016, there has been no significant improvement in
the longer-term mortality rate beyond the first year, where factors including malignancy,
antibody-mediated rejection, and cardiac allograft vasculopathy result in most cardiac
death.1,2 Post-transplantation injury is associated with various forms of programmed cell
death (PCD) that may severely compromise cardiac tissue viability, engage in innate and
adaptive immune responses, and promote inflammation to further exacerbate injury to the
graft. As long-term survival of organs has not been greatly improved by solely focusing
on recipient immunoregulatory mechanisms, developing new clinical treatment strategies
that target PCD and reduce inflammation in transplant organs, in conjunction with the
continued use of existing therapies involving immunosuppressants, may be crucial for
prolonging graft survival.3,4

1.2 Involvement of endothelial cells in heart failure
The endothelial cells that line the vascular endothelium perform critical roles in
maintaining vascular homeostasis. Some common functions include: regulating smooth
muscle tone, exchanging fluid and macromolecules between blood and surrounding
tissues, and participating in immune surveillance.5 Upon endothelial cell injury due to
innate or environmental stress post transplantation, vascular lesions occur. These
vascular lesions may progress from progressive thickening of the arterial intima layer to
formation of fatty plaque deposits and may, ultimately, result in heart failure.
One of the leading causes of endothelial cell injury is cell death, typically
apoptosis, where activation of intracellular proteases, named caspases, induce cells to
undergo nuclear fragmentation and formation of apoptotic bodies on the cellular
surface.6,7 This differs from necrosis, which is characterized by cellular swelling and
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rupture of the plasma membrane accompanied by inflammation.8 Here we discuss the
specific mechanistic pathways of cell death that occur in endothelial cells.

1.3 Pathways of endothelial cell death
Post-transplant graft injury can be triggered by various form of PCD, including
necrosis and apoptosis. Whereas necrosis includes “accidental” types of death which
result in the release of pro-inflammatory molecules, apoptosis is primarily mediated by a
cascade of caspase inducing double-stranded DNA breaks and resulting in plasma
membrane blebbing. Two independent apoptotic signaling cascades – the extrinsic and
intrinsic pathways – have been identified.

1.3.1

Apoptosis

Extrinsic apoptosis
The extrinsic apoptotic pathway is triggered by the binding of first apoptosis
signal receptor (Fas) or tumor necrosis factor receptor 1(TNFR 1). The Fas/Fas ligand
complex then recruits death domain-containing protein (FADD), pro-caspase 8, cellular
inhibitor of apoptosis protein (cIAPs), and cFLIPs to form the death-inducing signaling
complex (DISC). The DISC complex directly cleaves and activates pro-caspase 8, which
then triggers the activation of pro-caspase 3, the definitive enzyme for the execution of
apoptosis, promoting cytosolic and nuclear alterations for cell disassembly. Caspase 3
activates the caspase-activated DNase (CAD) through cleavage of the inhibitor of CAD
(ICAD), which then promotes double stranded DNA breaks and results in DNA
fragmentation7,9 (Fig 1).
Intrinsic apoptosis
Intrinsic apoptosis is controlled by mitochondrial enzymes9. After a cell is
stimulated by extracellular or intracellular stressors, pro-apoptotic members of the Bcl-2
protein family such as BAX and BAK accumulate at the mitochondria, resulting in
mitochondrial outer membrane permeabilization (MOMP) and the release of cytochrome
c and other pro-apoptotic mitochondrial molecules. Cytochrome c reacts with apoptotic
peptidase activating factor (APAF-1) and dATP to form the apoptosome complex10,11.
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This multiprotein complex activates caspase 9, which in turn cleaves effector caspases 3,
6, and 7. Mature caspases 3 and 7 cleave a large set of substrates resulting in the
morphological hallmarks of apoptosis, such as nuclear condensation, phosphatidylserine
exposure, and the release of membrane bound vesicles without cell membrane
permeabilization12,13. Similarly, opening of the mitochondrial pore stimulates the release
of apoptosis-inducing factor (AIF) and endonuclease G (EndoG) into the nucleus, which
triggers chromatin condensation and DNA fragmentation.14
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Fig 1. Extrinsic vs intrinsic apoptotic pathway Apoptosis can be categorized into the
extrinsic and intrinsic pathway. The A) extrinsic pathway can be stimulated by TNF
receptor superfamily cytokines such as FAS, TRAIl, or TNFα that result in the
aggregation of FADD and caspase 8 complex. Caspase 8 initiates the downstream
effector caspase 3 cleavage. Activated caspase 3 then triggers ICAD cleavage to release
the active CAD nuclease to promote DNA fragmentation. In contrast, the B) intrinsic
apoptotic pathway involves the mitochondrial pathway upon stimulation of stress signals,
triggering pro-apoptotic Bcl-2 protein family to accumulate in the mitochondrial pore,
promoting MOMP and causing the release of cytochrome c, apoptosis inducing factor
(AIF) and ENDO G, or Smac/DIABLO. Cytochrome c forms the apoptosome complex
along with Apaf-1/dATP/caspase 9 to trigger caspase 3 activation, and Smac/DIABLO
enhance apoptosis by inhibiting XIAP, where XIAP prevents caspase activation.

5

1.3.2

Necrosis
Necrosis is traditionally considered to be the primary form of inflammatory cell

death. Instead of the characteristic chromatin condensation, cell shrinking, and membrane
blebs in apoptosis, necrosis is defined by increased cell volume, organelle swelling,
lysosomal membrane permeabilization, and plasma membrane disruption.4,15 This results
in the leakage of non-membrane enclosed cytoplasmic contents including proinflammatory endogenous molecules such as heat shock proteins (HSP), high mobility
group box 1 (HMGB1), and uric acid, any of which can interact with the immune cells of
the transplanted organ.16 Multiple forms of necrotic-like cell death exist that display these
morphological hallmarks.
Necroptosis
Necroptosis is currently the most investigated pathway of regulated necrosis. This
regulated pathway features the necrotic morphology, but is mediated by receptorinteracting protein kinase (RIPK) and can be inhibited by Necrostatin-1 (Nec-1).
Necroptosis is induced by death receptors that include Fas and TNFα receptor. TNFα is a
pro-inflammatory molecule with important immunoregulatory roles in mammalian
immunity and cellular homeostasis.15,16
Upon stimulation of TNFR by TNFα, TNFR associated death domain (TRADD) is
recruited to the plasma membrane, which in turn recruits RIPK1, cellular inhibitors of
apoptosis protein-1 and 2 (cIAP1/2), linear ubiquitin chain assembly complex (LUBAC),
and TNF receptor-associated factor 2 and 5 (TRAF2/5) to form a receptor-bound
complex I that initiates downstream signaling events16,17. The polyubiquitination of
RIPK1 results in nuclear factor-κB (NF-κB) activation, leading to cell survival and the
release of pro-inflammatory cytokine. On the other hand, the deubiquitination of RIPK1
promotes cell death by associating with RIPK3, causing complex I to dissociate from the
membrane, forming a cytosolic complex II with recruitment of FADD and caspase 8. The
activation of caspase 8 will initiate apoptosis by cleaving RIPK1 and RIPK3, whereas its
inactivation by endogenous cFLIP-L or pharmacological caspase inhibitor (Z-IETD-fmk)
allows the formation of RIPK1-RIPK3 necrosome complex IIb. Activated necrosome
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complex then recruits mixed-lineage kinase domain-like protein (MLKL) that ultimately
induces cell rupture and necroptosis.17,18,19
Ferroptosis and oxytosis
Ferroptosis is an iron dependent form of PCD characterized by decreased
mitochondrial membrane densities, reduction of mitochondria crista, and eventual
mitochondrial membrane rupture.20,21 Mechanically, the small molecule ferroptosis
inducer erastin inhibits the amino acid transporter system Xc-Cys/Glu antiporter which
allows extracellular L-Cys and intracellular L-Glu exchange. This process leads to lipid
peroxidation accumulation and increase in iron metabolite ROS. Glutathione (GSH)
peroxidase 4 (GPX4), HSP, and nuclear factor erythroid 2 related factor 2 negatively
regulate ferroptosis by limiting ROS production and cellular Fe uptake, whereas positive
regulators such as NAPH oxidase and tumor protein p53 promote ROS mediated lipid
peroxidation.8,22
Similarly, inhibition of Xc-Cys/Glu antiporter results in oxytosis, where
downstream activation of 12-lipoxygenase initiates mitochondrial ROS and cyclic GMP
(cGMP). cGMP induces cGMP channel on the plasma membrane, stimulating Ca2+ influx
and lysosomal membrane permeabilization. Through inhibition of Xc-Cys-glu antiporter,
ferroptosis and oxytosis utilize iron and calcium metabolism – respectively – to induce
regulated necrosis.8,23
Parthanatos
Parthanatos, named after “Thanatos”, the personification of death in Greek
mythology, involves the accumulation of poly (ADP-ribose) polymerase (PARP) and
nuclear translocation of mitochondrial-associated apoptosis-inducing factor (AIF),
leading to large-scale fragmentation of DNA and cell death.24,25 The process depends on
the PARP activation which depletes cellular energy through reduction of nicotinamide
adenine dinucleotide (NAD+), an essential co-factor of glycolysis and TCA cycle.
Genetic deletion of poly-ADP-ribose polymerase-1 (PARP) demonstrates PARP plays an
important role in genotoxic stress, diabetes and neurodegeneration experimental models,
considering the fact that energy depletion is an important contributor in neuron and
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astrocyte cell death. Under normal physiological conditions, PARP1 localizes in the
nucleus and responds to DNA damage. If DNA damage is severe, however,
overactivation of PARP promotes parthanatic cell death.26 Studies have shown PAR
induces AIF release from the mitochondria and translation to the nucleus upon their
physical interaction26,27, leading to cell death, and the implication that, along with
manifesting through the necrotic pathway, apoptotic mechanisms also contribute to
parthanatic cell death.

1.4 Mitochondria regulated cell death
1.4.1

Mitochondria in endothelial cell death
As frontline defenders against vascular disease, microvascular endothelial cells

not only power the cardiomyocytes with oxygen delivery and energetic substrates, but
also play a role in preventing cardiovascular diseases post transplantation such as
atherosclerosis and cardiac vasculopathy.28 Furthermore, endothelial cells play a crucial
role in modulating mitochondrial function in the heart where endothelial cells outnumber
cardiomyocytes by nearly 3-fold.5 As proteins involved in mitochondrial homeostasis can
be involved in both apoptosis and necroptosis, it is important to place an emphasis on
better understanding the mechanisms of mitochondrial regulated cell death in order to
reduce injury an improve function in cardiac tissue.

1.4.2

Mitochondria plays a role in apoptosis and necroptosis
Mitochondria are known foremost as the primary cellular- energy- producing

organelles, but they also play a central role in cell death. Activation of death receptors
can lead to mitochondrial dysfunction events that can induce both apoptosis and
necroptosis.29,30 Stimulation of either death pathway depends on the availability of
caspases – recruitment of adaptor proteins, such as TRADD, will lead to activation of
caspase 8 and cleavage of B-cell lymphoma protein BID to induce mitochondrial pore
permeabilization. This permeabilization results in DNA fragmentation and apoptosis; in
the absence or inhibition of caspase 8, however, the TRADD adaptor protein complex
recruits RIPK1, which forms the necrosome complex with RIPK3. The RIPK1/3
complex, in turn, recruits MLKL, resulting in plasma membrane rupture and necroptosis.
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Fig 2. Mitochondria participates in apoptosis and necroptosis
Upon stimulation by TNFα or other ligands (TRAIL, FasL, TWEAK, LPS), an inner
membrane adaptor protein complex is formed along with RIPK1. Deubiqutinated RIPK1
leads to A) caspase 8 activation and Bid cleavage by caspase 2, which leads to the
opening of Bax/BaK pore in the mitochondrial membrane, subsequent AIF activation,
DNA fragmentation, and apoptosis. Under conditions where B) caspase 8 is inhibited,
RIPK1 and RIPK3 form the necrosome complex with MLKL. MLKL can be targeted to
both the plasma membrane to induce membrane rupture, or to the mitochondria triggering
ROS and necroptosis.
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1.4.3 BCL-2 family regulated mitochondrial dysfunction and
apoptosis
The B-cell lymphoma 2 (BCL-2) family proteins mediate mitochondrial apoptosis and
cell survival. The pro-apoptotic members include BCL-2 associated X protein (BAX),
BCL-2 homologous antagonist killer (BAK), BCL-2 interaction death promoter (BAD),
BH3 interacting-domain death agonist (BID), and BCL-2 interaction mediator of cell
death (BIM).31 Following a death signal, the pro-apoptotic members translocate to the
outer mitochondrial membrane (OMM) to be activated by BID, inducing
permeabilization of the OMM. This permeabilization stimulates the release of proapoptotic factors such as cytochrome c from their inner membrane space. The cytosolic
cytochrome c induces the formation of the apoptosome that activates effector caspases to
initiate apoptosis31,32

1.4.4 Mitochondrial permeability transition dysfunction
The mitochondrial permeability transition pore (mPTP) is a protein complex
suggested to span both the outer and the inner mitochondrial membranes, and is
presumed to perform important physiological roles.33,34 The precise molecular
composition of this pore remains highly controversial, but is thought to comprise of the
voltage-dependent anion channel (VDAC) on the outer membrane and adenine nucleotide
translocase (ANT) on the inner membrane (30), spastic paraplegia 7 (SPG7), phosphate
carrier (PiC), ATP synthase, and cyclophilin D (CypD).35 Recently, the role of VDAC
and ANT was questioned, where mitochondrial PT deficient in VDAC and ANT still led
to MPT onset.36 Furthermore, sensitivity to MPT inhibitor CsA (cyclosporine A) was still
displayed in VDAC and ANT null mitochondria.36
In normal conditions, the inner membrane channel opening is regulated to prevent
membrane potential dissipation and proton gradient loss. When stimulated by
intracellular signals unrelated to cell death, brief opening of mPTP (described as
“flickering”) causes transient mitochondrial membrane potential variations necessary for
cellular homeostasis such as mitochondrial Ca2+ extrusion during normal conditions.37
During Ca2+ overload and oxidative stress conditions, however, prolonged opening of the
mPTP is maintained, which promotes mitochondrial swelling, membrane potential loss,
ATP depletion, and, eventually, mitochondrial membrane permeabilization (OMM),
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which may result in cell death (30-34). Activation of OMM allows the release of the proapoptotic factors such as cytochrome c into the cytosol (31). These events are regulated
by the Bcl-2 protein family; pro-apoptotic proteins Bax and Bak allow membrane
permeabilization, while the anti-apoptotic members inhibit this process.32,38,39
The involvement of mitochondria, MPTP, and Bax/Bak as downstream
necroptotic mediators is still a point of contention. It has been suggested that
mitochondria play a role in regulated necrosis, where Bax/Bak generate a level of
permeability in the outer mitochondrial membrane in non-oligomerized forms.40 In
addition, it has been shown that necroptosis induced by DNA damaging agent (MNNG)
is dependent on Bax activation. It is possible that besides promoting apoptosis, the Bcl-2
family proteins may be required for necroptotic induction.41,42
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Fig 3. Molecular components of MPTP
mPTP plays an important role in cell death by opening up the mitochondrial membrane
through the formation of transporter channel proteins. Under apoptotic stimuli, prolonged
pore opening allows for entry of small molecules, such as Ca2+ and protons, causing a
loss of potential, osmotic imbalance, and mitochondrial swelling.
mPTP is thought to be composed of voltage dependent anion channel (VDAC), adenine
nucleotide translocator (ANT), peripheral benzodiazepine receptor (PBR), hexokinase
(HK), creatine kinase (DK), and cyclophilin D (Cyp-D). More recent research has
suggested that the VDAC and ANT may not be necessary for the mPT process, It is
suggested that MPTP complex now constitutes dimers of F0-F1 adenosine triphosphate
(ATP) synthase regulated by CypD, where CypD associates with the F1 component
oligomycin sensitivity-conferring protein (OSCP)to trigger pore opening, and that this
process is inhibited by CsA.43
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1.5 The role of cyclophilin in mitochondrial physiology
1.5.1

The role of cyclophilin in permeability transition
Although an agreement on the precise MPT pore components is yet to be reached,

the soluble protein CypD is the only unequivocally-established component of the pore
complex to date.44 CypD is a peptidylprolyl isomerase that is critical in regulating MPTP
opening. CypD resides in the mitochondrial matrix, which translocates to the inner
mitochondrial membrane during oxidative stress. CypD-deficient mitochondria were
resistant to calcium overload and protective against cardiac ischemia reperfusion injury,
whereas increased CypD level results in excessive ROS generation following ischemia
injury in rats.45
CypD is then suggested to mediate a conformational change in the adenine
nucleotide translocase and triggers mPTP opening, mitochondrial swelling, and release of
apoptotic effectors.46 Recently, it is proposed that CypD binds to ATP synthase, the
rotary enzyme responsible for ATP synthesis. The lateral stalk links the catalytic F1 and
the membrane bound F0 portion together. More specifically, it is proposed that CypD
may directly interact with the OSCP subunit of the lateral stalk, where, following
separation of individual lateral stalk subunits, CypD was found exclusively in the
immunoprecipitation with OSCP antibody.47,48

1.5.2

The role of cyclophilin in immune regulation
Aside from directly regulating the MPTP pore, Cyclophilin is also important in

regulating immune function through its interaction with cyclosporine (CsA).49 CsA is a
cyclic polypeptide metabolized by a number of fungi, and its effective
immunosuppressive properties revolutionized the field of transplantation since its
discovery in 1972.49,50 Binding of CsA with Cyclophilin A inhibits calcineurin function –
a calcium/calmodulin-dependent serine threonine protein phosphatase that activates the T
cell promoter IL-2 and inhibits the overall immune response.52 More specifically,
calcineurin inhibition prevents its substrate phospho-NFAT dephosphorylation and
translocation to the nucleus - a process necessary for IL-2 activation and subsequent T
cell activation.51
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1.6 Are mitochondria directly involved in programmed
necrosis?
The involvement of mitochondria and mPTP as downstream mediators in the
necroptosis pathway is still a point of contention. While it is well-established that
mitochondria are the platforms for apoptosis execution, the prospect of their direct
involvement in programmed necrosis remains controversial, and contradictory
experiments point towards either mitochondrial-dependent or –independent forms of
necrosis or necroptosis.
Evidence for the role of mitochondria in necroptosis:
Many studies have suggested that necrosome signalling might involve ROS
generation from the mitochondria.53 In addition, studies demonstrated necrotic death was
inhibited in endothelial cells with the mitochondrial antioxidant MnSOD.54,55 RIPK1,
RIPK3, and/or MLKL are translocated to the mitochondria during necroptosis and thus
result in ROS production.56 In particular, RIPK3 recruits MLKL to the necrosome
complex which is suggested to promote MLKL translocation to the mitochondria to
induce cell death – where MLKL expression is increased in mitochondrial fraction
following treatment of TNFα and pan-caspase inhibitor.
Genetics experiments confirmed the involvement of mPTP opening during PCD
where CyP-D KO in MEFs (mice embryonic fibroblast cells) resulted in a partial rescue
of necroptotic cell death 57,58in vitro,57,58 and that mPT pore is primarily involved in
necrotic cell death instead of apoptosis.59 In addition, studies have shown that siRNA
mediated knockdown of mitochondrial fission molecule Drp1 were able to inhibit TNFα
mediated necroptosis in HeLa and HT-29 cells.60 Furthermore, Drp1 depletion decreased
death in rat renal tubule epithelial cells after TNFα treatment.61 These studies all suggest
that mitochondria play a pivotal role in the execution of the necroptotic pathway.
Evidence against the role of mitochondria in necroptosis:
While studies demonstrated the role of mitochondrial dysfunction in necroptosis,
others suggested that mitochondria might be dispensable for this process. A previous
study revealed that, after mitochondrial depletion by mitophagy in SVEC and 3T3 cells,
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necroptosis was still observed.62 Another study also questioned the downstream RIPK3mitochondrial association, where RIPK3 or CypD ablation were protective individually,
but double knockout mice exhibited even greater protection,46 suggesting that the
necrosome and the MPT pore may be distinct pathways. However, CypD deletion did not
further attenuate myocardium ischemia reperfusion injury (IRI) to that conferred by
RIPK1 inhibition in the heart,63 which raises the question of whether tissue-and cell
specific differences may contribute to the coupling of MPT pore to necroptosis.

1.7 Rationale
Our previous studies have demonstrated that RIPK3-medidated necroptosis in
donor heart and kidney grafts can promote inflammatory injury and transplant rejection,
and that the inhibition of RIPK3 expression attenuated necrosis and reduced early graft
injury and rejection64,70. The down-stream pathway of necroptosis is not clear. It is
controversial whether mitochondria are involved in necroptosis. In our current study, we
aim to determine the role of CypD-regulated mPT in necroptosis in cardiac endothelial
cells and in mouse heterotopic transplantation model. This will provide rationale to
design an effective inhibition strategy to promote transplant tolerance.

1.8 Hypothesis
We hypothesize that Cyp-D inhibition can inhibit mPT, thus preventing cell
necroptotic death, and can trigger the release of proinflammatory CDAMP, preventing
graft injury in heart transplants and thus prolonging graft survival,.

1.9 Objectives
1. To determine if the inhibition of CypD function in cardiac endothelial cells can
prevent necroptotic death.
2. To determine if CypD deficiency in donor cardiac grafts can inhibit tissue injury and
prolong graft survival.
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Chapter 2

2

Materials and Methods

2.1 Animals
Male inbred C57BL/6 (B6), BALB/c mice and B6. Cyp-D-/- mice (Jackson Lab)
were maintained at the animal facility at Western University. All experimental
procedures were approved by the Animal Use Committee of Western University.

2.2 Heterotopic cardiac transplantation and post-operative
monitoring
Donor cardiac grafts were perfused with saline to remove blood after being
anesthetized with the mixture ketamine/xylazine according to the approved animal
protocol. The inferior vena cava and dorsal aorta were then clamped above and below the
cardiac graft. The graft was then removed, and intra-abdominal heterotopic cardiac
transplants were performed in our microsurgery laboratory in accordance with an
approved protocol. The recipient received sirolimus (rapamycin, LCL laboratories, USA)
from day 0 to day 9 post-transplantation (1 mg/kg mouse). Pulsation of the cardiac graft
was monitored daily. Cessation of pulsation was defined as the endpoint of rejection.

2.3 Histology and Immunohistochemistry
Grafts were collected on day 28, perfused with PBS, cut transversely, and then
either frozen using Tissue-Tek® O.C.T. Compound (Sakura® Finetek) or fixed with 5%
formalin for paraffin embedding. Paraffin sections were used for hematoxylin and eosin
(H&E) staining.
All injury scores were evaluated by a pathologist in a blinded manner. Graft
injury was evaluated based on change in endothelium as compared with naïve. Damage
was scored on a scale of 0–4 (0: no change, 1: 0-24% change, 2: 25-49% change, 3: 5074% change, 4: >75% change).
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2.4 Cell death assay
B6 and Cyp-D-/- microvascular endothelial cells (MVEC) were isolated and
developed as described previously (18-20). Cells were grown in complete Endothelial
Growth Media-2 (EGM-2 medium) supplemented with fetal bovine serum and growth
factors (Lonza, USA).
Human TNFα (hTNFa, 100 ng/ml; PeproTech, USA) was used to induce cell
death. Smac-mimetic (100 nM; Selleckchem, USA) was added to suppress the function of
Inhibitor of Apoptosis Proteins (IAP). This leads to caspase activation and inhibition of
RIPK1 polyubiquitination, and promotes apoptotic cell death. Caspase-mediated
apoptosis was inhibited by caspase-8 inhibitor Z-Ile-Glu-Thr-Asp-Fluoromethylketoe
(IETD, 10-30 μM; APExBIO, USA). Caspase-3 inhibitor Z-Asp-Glu-Val-AspFluoromethylketoe (DEVD, 10-30 μM;) and capase-9 inhibitor Z-Leu-Glu-His-AspFluoromethylketoe (LEHD, 10-30μM, APExBIO) were used. RIPK1 inhibitor
necrostatin-1s (Nec-1s, 10 μM; Merck Millipore, USA) or MLKL inhibitor GW806742X
(50-1000 nM, Synkinase, USA) were added to inhibit necroptosis. Mitochondrial
permeability transition events were inhibited with S-15176 (Sigma-Aldrich, USA). Dose
of S-15176 (1-20 μg/ml) was optimized and 16 µg/ml was chosen for the study.
Cyclosporin A (CsA) and control FK-506 (Sigma-Aldrich) were used for Cyp-D
inhibition. Dose of CsA (1-15 µg/ml) was optimized and 10 µg/ml was used for the
study. ROS inhibitors are 1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine (Tempol, 1-10
μM, Sigma-Aldrich, USA) and N-acetyl-L-cysteine (NAC, 1-10 μM, Sigma-Aldrich).
Dose was optimized and 10 μM was chosen for the study.
MVEC were seeded on 96-well flat-bottomed plates for 24 hours in complete
EGM-2 media (Lonza) to generate a confluent mono-layer. Cell death was detected either
a measure of SYTOX® Green Nucleic Acid Stain (100 nM, ThemoFisher, USA) and
Cell death (fluorescence intensity of SYTOX) was monitored using the IncuCyte
ZOOM® System (Essen Bioscience, USA). Cell death also conformed by 7-AAD
(eBioscience, USA) and analyzed bythe CytoFLEX flow cytometer (Beckman Coulter,
USA).
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2.5 Immunoblot analysis
MVEC were grown to a confluent monolayer and treated as described in cell
death assay. Cells were trypsinized, centrifuged at 300 g for 5 minutes and 50μL nuclear
lysis buffer (20 mM HEPES, 0.4 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1
mM PMSF) was added to each sample followed by a 30 minutes incubation at 37.5°C.
The nuclear fraction was collected by centrifugation at 10,000 g for 15 minutes at 4°C.
Equal amount lysates were loaded for gel electrophoresis. Protein was transferred
to a nitrocellulose membrane using electrophoresis blotting system (BioRad, USA). 5%
skim milk and 0.1% Tween-20 in Tris buffered saline was used for blocking.
The phosphorylated MLKL (pMLKL), Phospho S345 MLKL protein, was
detected using rabbit anti-mouse pMLKL antibody (Abcam, USA). Protein was
visualized using secondary anti-rabbit IgG horseradish peroxidase (HRP)-linked antibody
(Cell Signaling Tech. USA) and chemiluminescent substrate (EMD Millipore, USA).
Anti-β-actin antibody (Sigma-Aldrich, USA) was used as loading control.

2.6 shRNA-mediated Cyp-D RNA silencing and Real-time
PCR
Cyp-D shRNA (Dharmacon, USA) was transfected into MVEC using
Lipofectamine (Invitrogen, USA). Puromycin (Sigma-Aldrich, USA) was used for
antibiotic selection to eliminate untransfected MVEC. Cyp-D gene silencing was
confirmed by real-time PCR.
Total RNA from wildtype or shRNA transfected MVEC was extracted from tissue
or cells by Trizol extraction (Invitrogen, USA). cDNA was generated from RNA using
Superscript II (ThermoFisher, USA). Primers are: Cyp-D: CTC CAA CTC CAA GAA
CCC GC and TAA AAC AAT TCG GCC AAC TCG C; b-Actin: CCA GCC TTC CTT
CCT GGG TA and CTA GAA GCA TTT GCG GTG CA. Real-time quantitative PCR
was performed using a PCR reagent mixture (ABM, Canada) and the CFX Connect
(BioRad, USA). B-Actin amplification was used as the endogenous control.
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2.7 Statistical Analysis
Data was analyzed using the Student’s t-test for unpaired values. The Mantel-Cox
log rank test was used to determine graft survival differences. Differences were
considered significant when p-value ≤ 0.05.
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3

Results

3.1 Mitochondrial permeability participates in MVEC
necroptosis
We used wild type and RIPK3 deficient endothelial cells to determine the effects
of inflammatory cytokines on cell death. TNFα, Smac-mimetic, and caspase-8 inhibitor
IETD or RIPK1 inhibitor Nec-ls were added to wild type B6 and RIPK3-/- MVEC
cultures. In wild type B6 MVEC, treatment of TNFα increased cell death compared to
untreated cells. The addition of caspase-8 inhibitor IETD enhanced TNFα induced cell
death (Figure 4A), suggesting necroptotic death.64 Necroptosis in MVEC was inhibited
by the addition of RIPK1 inhibitor Nec-1s or RIPK3 deficiency in MVEC (Figure 4A).
To determine if mitochondrial dysfunction events play a role in necroptosis, mitochondria
transition permeability inhibitor S-15176 was added to MVEC. S-15176 prevents
collapse of the electrochemical gradient across the mitochondrial membrane and inhibits
release of apoptotic molecules.65,66 We found that the addition of S-15176 to
TNFα+IETD treated MVEC significantly reduced necroptosis (Figure 4B).
Opening of mPTP is largely regulated by Cyp-D. Cyp-D may regulate apoptotic
cell death as well necrotic cell death.67 It has been shown that Cyp-D deficiency in mouse
embryonic fibroblast cells resulted in a partial rescue of necroptotic cell death in vitro.57
However, another study showed that RIKP1/3 and mPTP/Cyp-D mediate two distinct
death pathway.46 We studied the role of Cyp-D in MVEC necroptosis. Initially, we used
CsA, a calcineurin inhibitor and classical immunosuppressive drug in clinical
transplantation that can bind to Cyp-D with high affinity and inhibit mPTP opening. CsA
inhibited TNFa-induced necroptotic cell death upon simultaneous caspase-8 inhibition
(Figure 1C). In contrast, FK506, a non-Cyp-D binding and calcineurin-inhibiting
immunosuppressive drug, did not inhibit cell death (Figure 1C), implying that Cyp-D, but
not calcineurin, participates in necroptosis.
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To further confirm the above findings, we developed MVEC from Cyp-Ddeficient mice. Cyp-D in wild type MVEC was silenced using Cyp-D shRNA (Figure
5A). Both Cyp-D silenced MVEC and Cyp-D deficient MVEC resisted TNFa-induced
necroptosis (Figures 5B&C). These data support that Cyp-D is a crucial molecule for
MVEC necroptosis.
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Figure 4. Mitochondrial permeability participates in MVEC necroptosis
(A) B6 MVEC and RIPK3-/- MVEC were plated on 96 well plate in triplicates and
treated with 100 ng/mL TNFα (T), 10 nM Smac mimetic (S) with or without 30μM
IETD(I) and 10 μM Nec-1s (N) with addition of SYTOX green. Cell death was quantified
by SYTOX fluorescent intensity with IncuCyte ZOOM live imaging system. Data at 24
hours were shown as mean ± SD and representative of at least 3 independent
experiments. (B) B6 MVEC necroptosis was induced as described above (TSI). mPTP
inhibitor S-15176 (16 ug/mL) was added. Cell death (SYTOX green uptake) was
monitored for 24 hours by IncuCyte ZOOM live imaging system. Data were shown as
mean ± standard deviation (SD) and representative of 3 independent experiments. (C)
CsA (10 ug/ml) and FK506 (10 ug/ml) were added in MVEC prior to necroptosis
induction. Data were shown as mean ± SD and representative of 3 independent
experiments. ****p≤ 0.0001, ***** p<0.00001, t-test.
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Figure 5. Cyp-D deficiency protects MVEC from necroptosis
(A) Cyp-D shRNA was transfected into MVEC followed by Puromycin treatment
for 2 weeks. Expression of Cyp-D RNA was analyzed by real-time PCR using a PCR
reagent mixture (ABM, Canada) and the CFX Connect (BioRad, USA). B-Actin
amplification was used as the endogenous control. Data were shown as mean ± SD and
representative of 3 independent PCR. (B) Cyp-D silenced MVEC were used to induce
necroptosis and cell death was quantified as described above. Data at 24 hours were
shown as mean ± SD and representative of 3 independent experiments. (C) MVEC were
isolated from a Cyp-D deficient mouse and then used for the necroptosis assay. Cell
death was quantified by SYTOX fluorescent intensity with IncuCyte ZOOM live imaging
system. Data at 24 hours were shown as mean ± SD and representative of 3 independent
experiments. ***p≤ 0.001, ***** p<0.00001, t-test.
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3.2 ROS and Caspases-3 and -9 do not contribute towards
MVEC necroptosis
Next we studied the down-stream mechanism of Cyp-D mediated necroptosis.
Opening of mPTP results in ROS release and activation of caspase-9 and its downstream
caspase-3. Recent studies showed that ROS play a crucial role in necrosis and that
inhibition of ROS prevents TNFα-induced necroptotic cell death.68,69 In our study,
addition of caspase-3 inhibitor (DEVD) or caspase-9 inhibitors (LEHD) did not attenuate
TNFa-induced necroptosis (Figure 6A). Similarly, addition of ROS inhibitors Tempol
and NAC did not inhibit necroptosis in MVEC (Figure 6B). These data suggest that ROS
or caspase-3 and -9 do not play significant roles in cardiac endothelial cell necroptosis.
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Figure 6. ROS, caspase-3 and caspase-9 do not participate in MVEC necroptosis.
(A) B6 MVEC were plated on 96 well plate in triplicates and treated with 100
ng/ml hTNFα (T), 100 nM Smac mimetic (S) with or without 30 μM IETD (I), 10 μM
Nec-1s (N), caspase-3 inhibitor DEVD (30 μM) or caspase-9 inhibitor LEHD (30 μM).
(B) ROS inhibitors NAC (10 μM) and Tempol (10 μM) were added to inhibit ROS
activities. Cell death was quantified by SYTOX fluorescent intensity with IncuCyte
ZOOM live imaging system. Data at 24 hours were shown as mean ± SD and
representative of 3 independent experiments. ***p<0.001, *****p<0.00001, t-test.
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3.3 Cyp-D mediated necroptosis is linked to MLKL
activation
MLKL is phosphorylated by RIPK3 and then migrates to lipid rafts where it
forms a pore, ultimately resulting in cell membrane rupture- a characteristic feature of
necroptosis.6 To investigate if Cyp-D mediated necroptosis is linked to MLKL activation,
MLKL inhibitor GW806742X was added and was observed to partially inhibit
necroptosis in MVEC (Figure 7A). MLKL siRNA silencing in MVEC (Figures 7B&C)
prevented necroptotic cell death (Figure 7D).
Next, we analyzed expression of phosphorylated MLKL (pMLKL), which is the
active form of MLKL, by western blot. pMLKL increased significantly in B6 MVEC
under necroptosis inducing conditions, which can be inhibited by Cyp-D inhibitor CsA or
by Cyp-D deficiency (Figure 7E), suggesting that Cyp-D is necessary for MLKL
phosphorylation during necroptosis.
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Figure 7. Cyp-D-regulated necroptosis is linked to downstream MLKL activation
(A) B6 MVEC necroptotic death was induced as in Figure 1. MLKL inhibitor
GW806742X (GW, 50-1000 nM) was added. Cell death was quantified by SYTOX
fluorescent intensity with IncuCyte ZOOM live imaging system. Data at 24 hours were
shown as mean ± SD and representative of 3 independent experiments. (B) MLKL was
silenced by pooled MLKL siRNAs (Santa Cruz). MLKL knockdown was confirmed by
real-time PCR 10 hours later. B-actin amplification was used as the control. Data at 24
hours were shown as mean ± SD and representative of 3 independent PCR. (C) MLKL
protein inhibition was confirmed 40 hours after by western blot using anti-total MLKL
and loading control anti-b-actin. The same result was obtained in a repeated experiment.
(D) MLKL knockdown protects MVEC from necroptotic death. 24 hours after siRNA
silencing, necroptosis was induced in MVECs . Cell death was measured by 7-AAD
positivity using flow cytometry. Data is a representative average of 3 independent cell
death experiments. (E) Analysis of MLKL phosphorylation. Necroptosis was induced in
B6 and Cyp-D-/- MVEC as described in Figures 1-3. Cells were collected 6 hours later
and cell lysates were analyzed for pMLKL by western blot using anti-phospho S345
MLKL. Antibodies against to total MLKL and house-keeping gene GAPDH were used as
controls. * p<0.05. ** p<0.01. *** p<0.001.
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3.4 Cyp-D deficiency in donor cardiac grafts attenuates
rejection
Our data indicate that Cyp-D may be an effective target to inhibit cell death. To
determine if Cyp-D deficiency in donor cardiac grafts can improve transplant survival,
we performed heterotopic transplantation of wildtype B6 or Cyp-D-/- hearts into BALB/c
mice followed by a brief period of immunosuppression spanning 0-9 days with sirolimus
(rapamycin) (18). Cyp-D-/- grafts survived significantly longer post transplantation
compared to wild type C57BL/6 grafts (89+43 versus 29+6, n=7, p<0.0001) (Figure 8A).
To assess graft injury, we collected the cohort grafts 28 days post-transplantation.
Naïve B6 hearts do not appear to be histologically different from naïve Cyp-D hearts
(Figure 9A). B6 grafts showed severe lymphocyte infiltration and endothelial damage
when compared to the Cyp-D-/- grafts collected 28 days post-transplantation (Figures
9B&C). However, tissue apoptosis was not significantly different between wild type and
Cyp-D-/- grafts as defined by anti-cleaved caspase-3 immunohistochemistry staining
(Figure 9D). In summary, these data suggest that Cyp-D deficiency protects cardiac grafts
from rejection.
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Figure 8. Cyp-D deficiency in donor cardiac grafts attenuated transplant rejection.
B6 or Cyp-D-/- cardiac grafts were heterotopically transplanted into abdomens of
BALB/c mice, followed by rapamycin (Rap) treatment (1 mg/kg, day 0-9). Grafts were
palpated and scored daily and considered rejected when pulsation ceased. (n=4-7,
***p<0.001, Mantel-Cox log-rank test).

Figure 9. Cyp-D deficiency in donor grafts inhibits endothelium damage.
(A) B6 or Cyp-D-/- cardiac grafts were transplanted into BALB/c mice as in
Figure 5. Recipients (n=4 per group) were euthanized 28 days post-transplantation and
grafts were collected for H&E staining and anti-cleaved caspase-3 immunohistochemistry
as detailed in the Methods. Microscope magnification=200 fold. Scale bar=100 µM. (B)
Endothelial damage and (C) graft lymphocyte infiltration were scored blindly by a
pathologist on a scale of 0=4 (0: no change, 1: 0-24% change, 2: 25-49% change; 3: 5074% change, 4: >75% change). (D) Quantification of the cleaved caspase-3 staining.
Positive areas were automatically quantified by pooling all areas of slides (Nikon
Eclipse). * p<0.05, t-test.
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Figure 10. Proposed mechanism of cell death.
Upon stimulation of TNFR by TNFα, TNFR associated death domain (TRADD)
is recruited to the plasma membrane, which in turn recruits RIPK1, cellular inhibitors of
apoptosis protein-1 and 2 (cIAP1/2), and TNF receptor-associated factor 2 and 5
(TRAF2/5) to form a receptor-bound complex I that initiates downstream signaling
events. The deubiquitination of RIPK1 via A20 or Cylindromatosis (CYLD) activity
causes complex I to dissociate from the membrane to form a cytosolic complex II with
recruitment of FADD and caspase-8 (Casp-8). Caspase-8 will initiate apoptosis via
cascades of caspases including caspase-3 (Casp-3), and cleave RIPK1 and RIPK3.
Inhibition of caspase-8 allows the formation of RIPK1-RIPK3 necrosome which recruits
and phosphorylates MLKL that ultimately induces cell membrane rupture and
necroptosis. Alternatively, the necrosome complex may also shuttle to the mitochondrial
membrane to induce prolonged mPTP opening and mitochondrial dysfunction. This may
promote downstream MLKL activation as well as release mitochondrial molecules that
mediate DNA breakage.
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4

Discussion

4.1 Summary
Solid organ transplantation remains a vital therapy for end stage heart failure.
Historically, post-operative care was emphasized; however, the alleviation of cellular
injury and subsequent inflammation gained more attention over the last few years. We
have demonstrated previously that programmed cell death, particularly RIPK3-mediated
necroptosis, can promote inflammation and tissue injury in donor heart and kidney grafts,
and inhibition of RIPK3 attenuated graft rejection.64,70,71 However, necroptosis molecular
pathways downstream of RIPK3 remain unknown. In this study, we demonstrated that
mitochondria are the critical component in the downstream necroptotic pathway;
specifically, inhibition of the mPTP regulator molecule Cyp-D attenuated MVEC
necroptosis in vitro, and Cyp-D deficient cardiac allografts showed prolonged survival
compared to wild-type C57BL/6 grafts post transplantation. Our study thus demonstrates
that mPTP participates in RIPK3 mediated necroptosis and contributes to inflammatory
injury in cardiac allografts, and that Cyp-D can be an important therapeutic target for
long-term graft survival.

4.2

MVECs necroptosis is mediated by mitochondrial
dependent mechanisms
It has been demonstrated the over the years that necroptosis is initiated by death

receptors such as TNFα, which leads to the downstream RIPK1/3 activation and
formation of the necrosome. This complex has been proposed to induce necroptosis via
mitochondrial independent or dependent pathways.30
The mitochondrial independent pathway involves MLKL mediated cellular
membrane rupture. Upon its phosphorylation by RIPK3, MLKL undergoes
conformational change, oligomerizes, and binds to plasma membrane lipids. Its N
terminal domain then perforates the membrane and induces DAMPs release. More
recently, MLKL has been additionally proposed to translocate to the mitochondria and to
induce mitochondrial ROS production and mitochondrial permeability increase. ROS in
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turn promote necroptosis by activating RIPK1 autophosphorylation, therefore creating a
positive feedback loop for necroptosis induction.72,73 In our study, however, ROS
inhibition did not result in significant reduction in cell death (Fig 6B), suggesting that
mitochondrial permeability may be a more significant contributor in death induction.
MLKL induced mitochondrial permeability increase induces cytochrome c
release, causing the formation of the supramolecular apoptosome complex with
deoxyATP, APF1, and pro-caspase 9.72,73Activated caspase 9 then activates the
downstream executer, caspase 3. Caspase 3 is key in promoting cellular disassembly and
nuclear fragmentation by activating CAD through inactivating the inhibitor of CAD
(ICAD).74,75 Following translocation to the nucleus, CAD homodimerizes and creates
double-stranded DNA breaks. In contrast, our study showed that inhibition of caspase 3
or 9 did not prevent necroptosis (Fig 6A). This suggests that other downstream
mechanisms may be responsible for mitochondrial dependent necroptosis induction, such
as mitochondrial molecules AIF and endonuclease G.76,77,78 As AIF and endonuclease G
have been characterized as apoptogenic factors, it would be interesting to investigate
whether they also participate in MVEC necroptosis.

4.3

The role of Cyp-D in organ injury
The involvement of mitochondria molecules as downstream RIPK mediators is

still a point of contention. While it is a well-established fact that mitochondria are
platforms for apoptosis execution, the prospect of direct mitochondrial involvement in
programmed necrosis remains controversial, and contradictory experiment results point
towards either mitochondrial-dependent or -independent forms of necroptosis.72 Our
study demonstrates that Cyp-D, as an essential component of mitochondrial permeability
transition regulator with an important role in apoptotic induction, also participates in
necroptosis and thus may be an important therapeutic target.
Genetics experiments confirmed that targeting Cyp-D protected cells from
necrosis, where CyP-D knockout in MEFs (mice embryonic fibroblast cells) resulted in a
partial rescue of necroptotic cell death 57in vitro, and that MPT pore is primarily involved
in necrotic cell death instead of apoptosis.80 We found that Cyp-D deficiency in donor
cardiac grafts attenuated rejection and promoted long term survival. The fact that cleaved
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caspase 3 expression was not significantly different between WT and Cyp-D null grafts
indicate that Cyp-D deficiency did not alter apoptotic tissue injury long-term. The data
suggests that Cyp-D dependent mitochondrial permeability contributes to DAMPs release
and augments inflammatory injury in the graft tissue.

4.4

Mediators of RIPK1/3/MLKL and mitochondrialdependent MVEC necroptosis
Even though our data suggested that mitochondrial permeability transition and its

regulator Cyp-D participates in necroptosis, the precise mechanism of MLKL
participation in the mPTP pathway following TNF and caspase 8 inhibition is
controversial. In Figure 7 we illustrated several possible MLKL pathways in the
necroptotic pathway. After caspase 8 inhibition, it is known that MLKL translocates to
the plasma membrane to induce membrane rupture and DAMP release. Alternatively, it
has been proposed that RIPK3 recruits MLKL and mitochondrial protein phosphatase
PGAM5 – a molecule suggested to be essential for mitochondrial fragmentation. PGAM5
recruits dynamin related protein Drp1 and dephosphorylates the serine 637 site of Drp1,
activating its GTPase.60 Drp1 then translocate to mitochondrial outer membrane division
sites and causes mitochondrial fragmentation.60
Drp1 activation has been shown to be involved in apoptosis, where under
apoptotic stimuli, Drp1 induced Bax oligomerization and mitochondrial cytochrome c
release81. Furthermore, Drp1 knockout Purkinje neurons displayed no signs of apoptotic
death82. Interestingly, Drp1 has also been implicated to play a role in necroptosis, where
it regulates mitochondrial division. Recent studies demonstrated that Drp1 mediated
mitochondrial division is mediated by RIPK1 and RIPK360. Thus the
RIPK3/MLKL/PGAM5/DRP1 is implicated to induce mitochondria - dependent
necroptosis. However, the contributions of PGAM5 and DRP1 in the necroptotic pathway
come under scrutiny as some studies suggest that PGAM5 and DRP1 may be dispensable.
In our study, activated MLKL increased significantly in the necroptosis induced MVECs,
but not in Cyp-D null MVECs, which suggests that Cyp-D activation is necessary for
downstream MLKL phosphorylation events. We observed multiple banding for
phosphorylated MLKL proteins, possibility due to the formation of MLKL multimers.
Further studies are needed to determine if RIPK1/3/MLKL may directly activate Cyp-D,
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or if it is activated through indirect pathways – for instance, others have suggested that
Cyp-D mediate Drp1 function and augment Drp1 recruitment to the mitochondria.

4.5

Strategy to prevent graft injury in transplantation
As novel immunosuppression methods have arisen over the past several years,

strategies that target intra-graft death and inflammation still hold great potential for
investigation. Currently, siRNA therapy has been utilized to target apoptotic molecules
such as caspases 3 and 8 during IRI in mice.83 However, when used on porcine kidneys,
caspase 3 siRNA delivery augmented inflammatory response and kidney tissue damage
instead,84 indicating a crucial need for a thorough knowledge of the complex
interconnected pathway mechanisms of apoptosis and necroptosis.
The mPT pore and its regulators have been recognized as drug targets for IRI and
neurodegenerative disorders, where Cyp-D knockout mice showed improved outcomes in
disease models compared to wildtype mice. The Cyp-D inhibitor CsA is a potent
immunosuppressive which disrupts calcineurin function and downstream immune cell
activation. However, the 17 different subtypes of Cyp-D in the human genome remain
poorly understood, and a comprehensive understanding of the similarities and differences
between Cyp-D subgroups is necessary for specific and effective drug design.85
Nevertheless, it would be interesting to determine which Cyp-D family would the most
effective target in the prevention of cell death without compromising mitochondrial
function, and to investigate delivery of that specific Cyp-D shRNA via viral vectors into
heart grafts to promote long-term tolerance.

4.6

Limitations
A limitation of the findings of this project is that the in vitro model may not

accurately represent the subsequent in vivo transplantation results. First, the usage of
small molecule inhibitors may yield multiple off-target effects. Second, the endothelial
cell lines may not accurately reflect the histological results in two aspects: 1) complex
pathways and immunological response may occur in vivo that are not seen in cell culture,
such as immune-mediated attack of T cells86, and 2) there are limitations to our KO
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models, where regions of genetic variability may exist due to the presence of “flanking”
genes incorporated into the genetic background87.
In terms of immunological study, it may be beneficial to do an initial investigation
into how immune response regulates cell survival (i.e. apply mixed lymphocyte reaction),
in addition to mitochondrial dysfunction in vitro beforehand, so as to better anticipate in
vivo transplantation results. To improve upon our in vivo model, we may consider siRNA
delivery into hearts88, 89, although it is for short-term silencing and therefore may not be
able to potentiate long-term protection in heart grafts post transplantation. CRISPR/cas9based strategy, on the other hand, may be a more promising area to explore.
Alternatively, we may consider viral particle delivery technology to achieve high
efficiency tissue delivery.

4.7

Conclusion

In this study, we demonstrated that mPTP plays an important role in necroptotic death of
cardiac cells and graft rejection. Additionally, inhibition of Cyp-D attenuated RIPK3downstream MLKL phosphorylation, leading to prolonged survival when compared with
wild type grafts. Our study shows that Cyp-D is an effective target in mitigating
necroptosis in MVEC and preventing cardiac graft rejection. As Cyp-D deficiency
prevents mPTP function without completely impeding mitochondrial function, targeting
Cyp-D may offer exciting therapeutic potential in the prevention of long-term graft
injury.

4.8 Overall project significance
Since long-term survival of transplants has not been greatly improved by posttransplant core strategies that solely target the immune response, a focus on
understanding tissue injury as characterized by cell death induced inflammatory events
may yield more effective strategies. Determining the role of mitochondria in regulated
cell death pathways may be crucial to expanding our as-yet incomplete understanding of
the downstream RIPK signaling in necroptosis. Therapeutically, we believe that targeting
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the mitochondria is a promising tactic in an effort to prevent regulated necrosis and
ultimately, to promote transplant survival.

4.9 Future Directions
While it is known that mPT downstream mechanisms is classically associated
with pro-apoptotic and necrotic stimuli, it is interesting that caspase 3 and ROS do not
significantly contribute to MVEC death. This suggests that other mediators may be at
play for necrotic DNA damage which is independent of caspase ROS, for instance,
apoptosis-inducing factor and endonuclease G (EndoG). After released into the cytosol,
AIF and EndoG translocate to the nucleus an is responsible for large scale DNA
fragmentation. AIF and EndoG participate in apoptosis, but further investigation into
their roles, or lack thereof, in necroptosis may also be warranted. Importantly, it will be
crucial to translate our findings to clinically relevant study, by using a viral vector to
deliver shRNA into heart grafts in order to inhibit Cyp-D and promote long-term
survival.
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